Aggregate Spend Laws: Here Comes the Sun

There appears to be a slow-moving train collision looming for the US pharma industry over aggregate spending rules, for which data collection is supposed to begin on January 1. Having been called “the most disruptive force affecting pharma sales and […]

Read More

2010 Product Security Report

To amend the well-known saying about national defense, “Eternal vigilance is the price of pharmaceutical brand integrity.” But while there are various efforts to tighten supply chain security in pharma distribution, especially in selected countries outside the US, the industry […]

Read More

A Process-Based Approach To Aggregate Spend

Interactions between life sciences companies (pharma, biotech and med-device) and various healthcare providers (HCPs) and institutions (HCIs) over the past decade have been under increased scrutiny. The life sciences industry’s various interactions with HCPs/HCIs have led to: • Revisions to […]

Read More

Smoothing the Path to Drug Safety

The FDAA Act of 2007 empowered the FDA to require Risk Evaluation and Mitigation Strategies (REMS) for new and existing pharmaceutical products. After the first programs were introduced in 2008, REMS have now become an established part of the pharmaceutical […]

Read More